SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : World Heart Corp - WHRT and TSE/WHT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: the Chief who wrote (264)5/23/1999 11:01:00 PM
From: Mindshare  Read Replies (1) of 500
 
The most serious weak link of the DeBakey VAD is it has no failsafe mode, which is one of your points. Adding additional devices in the blood flow to prevent recirculation would be like adding a trailer hitch to a classic car (something you don't want to do unless its absolutely necessary). I think the approach that will be taken is to make the device so reliable (back-up controllers and batteries, super tough wires, etc...) that device failures are so low that its acceptable. Add in some diagnostics for early failure detection and MAYBE a check valve won't be needed. Insurance companies and liability lawyers may not see it that way. It's a sticky point.

Clotting and pulse issues will likely not be a concern for the DeBakey VAD in long term implants. Of the ten people who have received the device, only one had clotting problems. The clot is thought to have been generated in the patients own heart and washed into the pump. The pulse of long term implants will only get better in time with the majority of patients.

Your disclaimer had me laughing. Nice to see a good sense of humor.

Regards
Mindshare
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext